Field report SW-96 / N1 · sheet /macro
Boardroom MacroFiled from the territory
Bristol Myers CEO Boerner Warns U.S. Biopharma Lead 'Not a Birthright'
Bristol Myers Squibb CEO Chris Boerner warned the day the U.S. lost measles elimination that America's biopharma lead — 90% of new drug launches — "is not a birthright."
- Grid
- SW-96 / N1
- Surveyed
- November 18, 2026
- Reading
- 4 min read
- Correspondent
- Elena Vasquez

Field notes
- PAHO revoked U.S. measles-elimination status on Tuesday; the CDC has counted over 5,400 cases in 2026 after 2,289 last year.
- 90% of new medicines launch in the U.S., often two to three years before other rich countries, Boerner said.
- Kindergarten MMR coverage fell to 92.4%, below the 95% herd-immunity threshold, with record 4.2% exemptions.
- BMS will merge R&D into one organization under CMO Cristian Massacesi from Jan. 1, targeting a 30% faster clinic-to-approval timeline.
- Medicines are 10–15% of U.S. health spending; roughly 50 cents per branded-drug dollar goes to middlemen, Boerner said.
The U.S. biopharma industry's global dominance is earned, not inherited, Bristol Myers Squibb CEO Chris Boerner said on Tuesday — the same day the Pan American Health Organization stripped the United States of its measles-elimination status.
Speaking at the Fortune 500 Innovation Forum in Detroit after Fortune's Diane Brady opened their conversation with the news, Boerner framed the loss as a warning that extends far beyond one virus. America leads the world in new medicines, he said: 90% of them launch in the U.S., often two to three years before other wealthy countries get access.
"That's a real benefit that we have, but it's not a birthright," Boerner said.
What does losing measles elimination mean?
PAHO ruled on Tuesday that the U.S. no longer meets the standard it first cleared in 2000: no single chain of measles transmission lasting 12 months or longer. Mexico and Bolivia lost their status as well; Canada lost its own last year.
The CDC has counted more than 5,400 measles cases so far in 2026, up from 2,289 last year, according to CBS News. Many began in outbreaks in close-knit Mennonite communities before spreading.
The underlying numbers have been deteriorating for years:
- 92.4% of U.S. kindergartners received MMR shots in the 2025–26 school year, per CDC data — down from 95.2% before the pandemic.
- That falls below the 95% threshold epidemiologists say measles herd immunity requires.
- Vaccine exemptions hit a record 4.2%.
What keeps the U.S. ahead?
Boerner named no names — not Health Secretary Robert F. Kennedy Jr., not any specific policy. But he listed what he sees as the pillars of American biomedical leadership: a public-private partnership built around the NIH, a deep biotech sector, access to capital, drugmakers that operate from discovery through sale, and "an FDA that's the sort of global standard." Beneath all of it, he said, sits "a respect for science."
"Whenever you undermine any piece of that ecosystem, it impacts the whole," he said. "If we want to continue to benefit from advanced therapies, including some of the world's best vaccines, I think we need to be mindful of improving that ecosystem and being very careful about policies that don't."
Pressed on his personal reaction, he called the measles news "clearly troubling."
His restraint contrasts with Pfizer CEO Albert Bourla, who told investors last December that "science is replaced with political beliefs" at HHS, BioSpace reported. Asked at Davos in January what blocks a better vaccine conversation, Bourla answered: "The Secretary of Health."
Where does Boerner agree with the White House?
In December 2025, Bristol Myers was one of nine drugmakers to sign most-favored-nation pricing deals with the White House. On Tuesday, Boerner credited the president with getting one thing "absolutely" right: other countries "are not paying their fair share." He pointed to the U.K.'s pledge, in its pharmaceutical trade deal with the U.S., to double its spending on innovative medicines over roughly a decade.
On costs, Boerner turned on the wider system. Medicines account for about 10% to 15% of U.S. health spending and have for a decade, he said, so "we got to bring the other 85% to the table." Roughly 50 cents of every dollar spent on a branded drug goes to parties who had no role in discovering or developing it. "That screams inefficiency," he said, borrowing the president's word: "middlemen."
He said BMS runs assistance programs for uninsured and underinsured patients but is "prohibited by statute" from extending them to people on Medicare. "That's unacceptable. We should fix that." He added he would gladly accept higher payments when a drug works and lower payments when it does not — deals U.S. rules make difficult, which is why BMS strikes far more of them abroad.
How is BMS restructuring R&D?
Last week, BMS said it will fold research and development into a single organization under chief medical officer Cristian Massacesi, effective Jan. 1. Chief research officer Robert Plenge will depart after an advisory stint through March. The traditional boundaries between research and development "are collapsing," Boerner said in the announcement.
AI is one driver. The technology lets BMS run in parallel work that once happened in sequence, he told Brady. The company has committed to cutting the time from clinical entry to approval by 30% — a target Boerner thinks AI "will beat that by a mile."
The CDC played down Tuesday's designation. "The measles elimination designation is not what protects Americans. Vaccination does," CDC Director Dr. Erica Schwartz said in a statement, citing $100 million the agency has sent to state and local health departments.
PAHO expects the U.S. to submit a plan within weeks to stop transmission; regaining status requires at least a year without an unbroken chain of spread. Boerner's prescription reached wider than one virus. "We've got to be mindful of the entire ecosystem," he said, "and treat it like an ecosystem."
via fortune.com/feed/ (Source)
More from Elena Vasquez
Show full bio
Staff writer covering companies, deals and strategy in corporate strategy and chief-executive leadership at CEO Frontier.
486 articles
Adjacent sheets
- CSL to Cut Up to 15% of Workforce, Trim R&D and Spin Out Vaccines
- FDA Panel Backs Galleri Blood Test for 50-Plus Cancers
- ImmunityBio Falls 19% After Revenue Miss and Going-Concern Warning
- Defensive Stocks Surge as Investors Abandon AI-Heavy Tech Trade
- AstraZeneca weighs cancer vaccines as Phase 3 data emerge